TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American ...
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...
August 11, 2025 - Previous articles in this series have explored identification, preservation, collection, review and production of novel data sources, but I would be remiss if I left out the last, ...
-- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32 nd annual ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ...
Many Data Summit speakers have made their presentations available online for attendees to view. Presentations will remain on the website during and after the conference so that you can refer to them ...
Twelve-month data from the VOLT-AF Global IDE study found that the Volt PFA System had an industry-leading success rate (84.2%) of freedom from documented rhythm recurrence among all competitive PFA ...
Tempus AI TEM shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results